ArticleBioengineering (Basel, Switzerland)2025
Bayesian Hierarchical Modeling for Variance Estimation in Biopharmaceutical Processes.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Determining process variances in biopharmaceutical manufacturing is challenging due to limited data availability. To address this, we introduce a Bayesian hierarchical model designed for meta-analysis of process variance. This approach can improve process variance estimation by integrating data from multiple products, providing more reliable estimates of critical quality attributes in cases of data scarcity. Additionally, our model aids in evaluating process models, ensuring quality in process development. The paper demonstrates the new method using a simulation study, showcasing its potential to leverage historical data for both upstream and downstream phases of future CMC drug development. The new statistical model has great potential to expedite the market introduction of therapies while ensuring patient safety, allowing new treatments to reach patients more quickly without compromising quality or efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.